AxiomBio

Axiom, founded in 2024 in San Francisco, US, specializes in predictive models for drug toxicity.Axiom specializes in providing advanced AI-driven models that predict drug toxicity with greater accuracy and affordability compared to traditional laboratory and animal testing methods. The core offering includes tools that leverage the world's largest dataset of primary human liver biology to forecast clinical outcomes related to liver injury, among other applications. These models enable pharmaceutical scientists to identify and mitigate toxicity risks early in the drug development process, effectively addressing a significant cause of clinical trial failures. Axiom's customer base consists of major pharmaceutical companies and research institutions globally, with a particular focus on markets in North America and Europe.Axiom's revenue model is primarily structured around partnerships with pharmaceutical companies, where clients engage in subscription-based agreements to access its AI modeling services. These transactions typically involve a fee-for-service arrangement, where clients pay for the usage of Axiom's predictive tools, potentially encompassing various offerings, including liver toxicity assessments. Pricing plans for these services range from USD 5,000 to USD 15,000, depending on the specific needs of the client and the complexity of the analysis required. By providing robust predictions that streamline the drug development process, Axiom supports its partners in reducing costs associated with late-stage failures, thereby enhancing their overall R&D productivity. The company plans to support pilot studies with pharmaceutical and biotechnology partners. Axiom is targeting expansion into European markets by the end of 2025, focusing on collaboration with additional pharmaceutical companies to enhance its service offerings.

1. Seed

   Jun 1, 2023

   Amount

   $7M

   Investors

   Locked